“The CVProfilor^® DO-2020 System provides physicians with a better way to identify those patients at risk for cardiovascular disease by providing information that goes beyond the blood pressure cuff,” said Greg H. Guettler, president of Hypertension Diagnostics, Inc. “Providing physicians with information regarding large and small artery elasticity indices allows them to differentiate between patients with prematurely stiffened arteries (a sign of vascular disease) and those with elevated blood pressure. Since more than half of the patients who suffer from a heart attack had normal blood pressure readings, this is an important new parameter to both physicians and patients. By incorporating the CVProfilor^® DO-2020 into a physician’s practice, we just may be able to identify those people destined to have a future morbid event,” added Guettler.

The CVProfilor^® DO-2020 System improves patient care by allowing physicians to non-invasively detect a premature loss of arterial elasticity in the microvasculature, by providing new clinical information on the cardiovascular health of patients, by expanding vascular disease assessment to include teens and young adults, by monitoring the effects that cardiovascular drugs have on vascular elasticity, and by establishing a baseline for vascular disease risk.

Hypertension Diagnostics, Inc. designs, develops, manufactures and markets proprietary cardiovascular profiling systems for medical applications and clinical research. These systems are marketed to physicians, other health care professionals and researchers by a direct sales force and via distributors throughout the world. In addition to providing blood pressure values, the systems non-invasively detect subtle changes in the compliance or elasticity of both large and small arteries which is a unique feature of HDI’s technology.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2001 Annual Report on Form 10-KSB under the caption “Risk Factors,” as well as others not now anticipated.

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
  
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Investor Relations: Jens Dalsgaard and Tony Altavilla,
Managing Directors
Redwood Consultants, LLC
Mill Valley, CA 94941
415-380-0500

Contact: Greg H. Guettler, President